The global primary care POC diagnostics market size was estimated at USD 6.3 billion in 2016. The rapid evolution of point-of-care testing (POCT) holds enormous potential for the growth of both primary and secondary care settings. Rapidly increasing healthcare expenditure within secondary and tertiary care has driven the attention of healthcare communities toward primary care settings. This expenditure issues can be curbed to a great extent at the primary care stage through routine screening of patients with early symptoms. As a result, the market for primary care POC diagnostics is likely to receive a major boost.
Companies within the market are undertaking continuous efforts for the advancement of POC products concerning their portability and ease-of-use. This is mainly to ensure effective and unrestricted usage of POC devices at primary care levels and in remote settings with no/minimal laboratory infrastructure. In the current scenario, POCT is successfully implemented for disease diagnosis in outpatient settings, which include non-practice clinics, urgent care, and physicians’ offices and clinics.
Demand for POC technologies from primary care physicians is likely to grow significantly over the years. This is due to a paradigm shift in diagnostics from centralized labs towards practitioners’ offices, which in turn, would open new revenue streams for various end-users and significantly improve profit margins.
Higher adoption of POC testing in primary care is observed in remote locations as well as relatively densely populated regions where telehealth services are being actively considered to improve patient convenience. The decentralization of primary care services in several markets around the world has become a common trend as it helps reduce the use of antibiotics and offers rapid results. This is expected to drive the adoption of POCT in the market.
Growing usage of POCT in primary care settings can also be attributed to ease-of-usage associated with these devices in out-of-hospital laboratory settings. Also, medical as well as non-medical personnel can use these devices with minimum training.
POCT devices and products include primary care systems, feces testing, Hb1Ac testing, decentralized clinical chemistry, cardiac markers, hematology, fertility, lipid testing, cancer marker, urinalysis, coagulation, drug abuse testing, glucose testing, blood gas/electrolytes, thyroid-stimulating hormone, infectious diseases, and ambulatory chemistry. The rising availability of these devices, ongoing studies on their usage, and continuous technological advancements are expected to drive the primary care POC diagnostics market.
Glucose testing is a major segment within the market. Adoption of self-testing glucose devices plays an important role in controlling glycemic levels regularly, which, in turn, is anticipated to provide positive health outcomes, especially among diabetics.
Lipid testing products are expected to witness strong growth over the forecast period. Commercial availability of several Clinical Laboratory Improvement Amendments of 1988 (CLIA)-waived POC lipid testing products in the market is likely to drive the segment considerably. F. Hoffmann-La Roche Ltd.’s Accutrend Plus system is a significant example of such testing products, which can be effectively employed in physicians’ offices and clinics. Ongoing research studies and support from funding agencies are also expected to boost the segment throughout the forecast period.
A global rise in POCT owing to easy and quick results has radically improved workflow and patient care at physicians’ offices. These tests, supported by the expertise of doctors in quickly assessing the situation and making important medical decisions, deliver improved clinical outcomes. POCT also aids in performing complex tests with low sample volumes compared to those performed in laboratories. Thus, factors such as consumer demand for easy, stress-free, and less time-consuming tests are likely to boost the market for primary care POC diagnostics in physicians’ offices.
The pharmacy and retail clinics segment is also expected to witness steady growth over the forecast period. An increase in the number of people covered under healthcare plans has resulted in a reduction in healthcare costs and improved access to healthcare. This has led to the availability of POC testing at pharmacies. In the last five years, the number of pharmacists performing laboratory tests such as cholesterol screening and glycosylated hemoglobin (A1C) has increased. Moreover, an increasing number of patients prefer to undergo testing for acute and chronic diseases at pharmacies, thus providing the segment lucrative opportunities for growth.
North America held the largest share in 2016 owing to a substantial number of primary care settings in the U.S. that employ POC products. The presence of major players in the country offering products and services for primary settings has also attributed to the large share of this regional market. The Centers for Medicare & Medicaid Services is urging healthcare providers to initiate patient engagement programs. This, along with the availability of funding for R&D in healthcare by universities and academia, is driving the market.
The North American market is relatively more developed compared to the rest of the world and this can be attributed to the availability of numerous advanced and innovative POC diagnostic solutions. Growing demand for these solutions in primary home healthcare and assisted healthcare settings is also a key growth driver. The introduction of advanced healthcare solutions such as EHR, digitalization, and telemedicine also works in the market’s favor.
However, Asia Pacific is expected to emerge as a lucrative regional market and is slated to exhibit a stronger growth rate compared to other regions. This can be attributed to an increasing number of firms engaged in capitalizing untapped potential in the region. Moreover, growing awareness among the population about early disease diagnoses to improve patient survival rate is expected to spur the market in the Asia Pacific.
Some of the key players operating in the market are Roche Diagnostics, BD Biosciences, Danaher Corporation, Abbott Laboratories, Instrumentation Laboratory, bioMerieux, Siemens Healthcare, and Quidel Corporation.
Partnerships and agreements are a major trend observed in the market. These companies have been drafting agreements with prominent emerging participants to establish co-ownership in IP and to gain key licenses and sub-licenses from various universities for foundation IP rights. Companies are also engaged in collaborations with major players to develop new product lines and enhance their market presence.
Report Attribute |
Details |
The market size value in 2020 |
USD 7.36 billion |
The revenue forecast in 2025 |
USD 8.65 billion |
Growth Rate |
CAGR of 3.5% from 2018 to 2025 |
The base year for estimation |
2016 |
Historical data |
2014 - 2016 |
Forecast period |
2018 - 2025 |
Quantitative units |
Revenue in USD Million & CAGR from 2018 to 2025 |
Report coverage |
Revenue forecast; company share; competitive landscape; growth factors and trends |
Segments covered |
Product, application, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; Germany; U.K.; France; Italy; Spain; China; Japan; India; Korea; Australia; Singapore; Brazil; Mexico; Chile; Argentina; South Africa; Saudi Arabia; UAE; Qatar; Nigeria; Kenya; Zimbabwe |
Key companies profiled |
Roche Diagnostics; BD Biosciences; Danaher Corporation; Abbott Laboratories; Instrumentation Laboratory; bioMerieux; Siemens Healthcare; Quidel Corporation. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country; regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For this study, Grand View Research has segmented the global primary care POC diagnostics market report based on the product, end-use, and region:
Product Outlook (Revenue, USD Million, 2014 - 2025)
Glucose Testing
Hb1Ac Testing
Coagulation
Fertility
Infectious Diseases
Cardiac Markers
Thyroid Stimulating Hormone
Hematology
Primary Care Systems
Decentralized Clinical Chemistry
Feces
Lipid Testing
Cancer Marker
Blood Gas/Electrolytes
Ambulatory Chemistry
Drug Abuse Testing
Urinalysis
End-use Outlook (Revenue, USD Million, 2014 - 2025)
Pharmacy & Retail Clinics
Pharmacy & Retail Clinics, By Product
Glucose Testing
Hb1Ac Testing
Coagulation
Fertility
Infectious Diseases
Cardiac Markers
Thyroid Stimulating Hormone
Hematology
Primary Care Systems
Decentralized Clinical Chemistry
Feces
Lipid Testing
Cancer Marker
Blood Gas/Electrolytes
Ambulatory Chemistry
Drug Abuse Testing
Urinalysis
Physician Office
Physician Office, By Product
Glucose Testing
Hb1Ac Testing
Coagulation
Fertility
Infectious Diseases
Cardiac Markers
Thyroid Stimulating Hormone
Hematology
Primary Care Systems
Decentralized Clinical Chemistry
Feces
Lipid Testing
Cancer Marker
Blood Gas/Electrolytes
Ambulatory Chemistry
Drug Abuse Testing
Urinalysis
Urgent Care Clinics
Urgent Care Clinics, By Product
Glucose Testing
Hb1Ac Testing
Coagulation
Fertility
Infectious Diseases
Cardiac Markers
Thyroid Stimulating Hormone
Hematology
Primary Care Systems
Decentralized Clinical Chemistry
Feces
Lipid Testing
Cancer Marker
Blood Gas/Electrolytes
Ambulatory Chemistry
Drug Abuse Testing
Urinalysis
Non-practice Clinics
Non-practice Clinics, By Product
Glucose Testing
Hb1Ac Testing
Coagulation
Fertility
Infectious Diseases
Cardiac Markers
Thyroid Stimulating Hormone
Hematology
Primary Care Systems
Decentralized Clinical Chemistry
Feces
Lipid Testing
Cancer Marker
Blood Gas/Electrolytes
Ambulatory Chemistry
Drug Abuse Testing
Urinalysis
Regional Outlook (Revenue, USD Million, 2014 - 2025)
North America
The U.S.
Canada
Europe
Germany
France
U.K.
Italy
Spain
Asia Pacific
China
Japan
India
Korea
Australia
Singapore
Latin America
Brazil
Mexico
Chile
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Nigeria
Qatar
Kenya
Zimbabwe
b. The global primary care POC diagnostics market size was estimated at USD 7.10 billion in 2019 and is expected to reach USD 7.36 billion in 2020.
b. The global primary care POC diagnostics market is expected to grow at a compound annual growth rate of 3.48% from 2018 to 2025 to reach USD 8.65 billion by 2025.
b. Pharmacy & retail clinics dominated the primary care POC diagnostics market with a share of 44.3% in 2019. This is attributed to increase in the number of people covered under healthcare plans, which has resulted in improved availability of point of care testing at pharmacies.
b. Some key players operating in the primary care POC diagnostics market include Roche Diagnostics, BD Biosciences, Danaher Corporation, Abbott Laboratories, Instrumentation Laboratory, bioMerieux, Siemens Healthcare, and Quidel Corporation.
b. Key factors that are driving the market growth include rapidly increasing healthcare expenditure within secondary & tertiary care and companies ensuring effective as well as unrestricted usage of point of care devices at primary care levels.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.